Zoetis Inc. (ZTS): Operating Cash Flow
$2.90B
Year ended 2025-12-31
+14.9%
3-year compound annual growth
+6.4%
5-year compound annual growth
+15.9%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.90B | -1.7% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $2.95B | +25.5% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $2.35B | +23.1% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $1.91B | -13.6% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $2.21B | +4.1% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $2.13B | +18.4% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $1.79B | +0.3% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $1.79B | +33.0% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $1.35B | +88.8% | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | $713.00M | +7.4% | 2019-02-14, From 2016-01-01 |
| 2015-12-31 | $664.00M | +6.1% | 2018-02-15, From 2015-01-01 |
| 2014-12-31 | $626.00M | -8.1% | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | $681.00M | +50.0% | 2016-02-24, From 2013-01-01 |
| 2012-12-31 | $454.00M | -8.7% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $497.00M | n/a | 2014-03-26, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.90B | -1.7% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.40B | -12.3% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $3.63B | n/m |
| Viatris Inc (VTRS) | 2025-12-31 | $2.32B | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.98B | +12.6% |
| Organon & Co. (OGN) | 2025-12-31 | $700.00M | -25.5% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $1.13B | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.65B | +32.2% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $560.00M | +3.5% |
Compare ZTS, BHC, VRTX, VTRS side by side · Screen every company in Pharmaceutical Preparations ↗